Wockhardt Of India Said Eyeing MNCs To Share Biosimilar Work
This article was originally published in PharmAsia News
India's Wockhardt is in the market for a multinational partner for its biosimilar business. The company is said to be negotiating with MNCs such as Eli Lilly, Pfizer, Sandoz and Sanofi-Aventis. Wockhardt is willing to sell a half-interest share in its biosimilar division, according to one source, even though that would mean spinning it off into a separate company. Such a merger, however, would not be expected to be completed for another year. (Click here for more
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.